Bahl & Gaynor’s Cardinal Health CAH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.3M Buy
6,149
+403
+7% +$86.8K 0.01% 223
2025
Q4
$1.18M Buy
5,746
+906
+19% +$171K 0.01% 229
2025
Q3
$760K Sell
4,840
-15
-0.3% -$2.32K ﹤0.01% 250
2025
Q2
$816K Hold
4,855
﹤0.01% 250
2025
Q1
$669K Buy
4,855
+870
+22% +$111K ﹤0.01% 266
2024
Q4
$471K Hold
3,985
﹤0.01% 286
2024
Q3
$440K Buy
3,985
+150
+4% +$15.7K ﹤0.01% 293
2024
Q2
$377K Hold
3,835
﹤0.01% 298
2024
Q1
$429K Buy
+3,835
New +$414K ﹤0.01% 299
2017
Q4
Sell
-3,559
Closed -$238K 410
2017
Q3
$238K Hold
3,559
﹤0.01% 380
2017
Q2
$277K Sell
3,559
-199
-5% -$15K ﹤0.01% 380
2017
Q1
$306K Sell
3,758
-270
-7% -$21.3K ﹤0.01% 356
2016
Q4
$289K Buy
4,028
+270
+7% +$19.5K ﹤0.01% 358
2016
Q3
$292K Buy
3,758
+1
+0% +$81 ﹤0.01% 358
2016
Q2
$293K Buy
3,757
+557
+17% +$44.4K ﹤0.01% 363
2016
Q1
$262K Sell
3,200
-528
-14% -$42.9K ﹤0.01% 371
2015
Q4
$333K Buy
3,728
+228
+7% +$19.4K ﹤0.01% 356
2015
Q3
$269K Hold
3,500
﹤0.01% 381
2015
Q2
$293K Buy
3,500
+1,000
+40% +$88.3K ﹤0.01% 394
2015
Q1
$226K Buy
+2,500
New +$215K ﹤0.01% 413

Other funds holding CAH

Bahl & Gaynor's CAH Position: Q1 2026 in Review

Bahl & Gaynor increased its Cardinal Health (CAH) stake by 7% in Q1 2026, buying an estimated $86.8K and bringing the position to 6,149 shares worth $1.3M. The position accounts for 0.01% of the portfolio, ranked #223.

Bahl & Gaynor first reported a position in CAH in Q1 2015 and has held it in 20 quarters since. 1,429 funds tracked by Wall St. Rank hold CAH as of Q1 2026.

  • Bahl & Gaynor held 6,149 shares of Cardinal Health worth $1.3M as of Q1 2026.
  • Bahl & Gaynor bought 403 Cardinal Health shares in Q1 2026, an estimated $86.8K.
  • Cardinal Health made up 0.01% of Bahl & Gaynor's portfolio in Q1 2026, its #223 holding.
  • Bahl & Gaynor first reported a position in Cardinal Health in Q1 2015 and has held it in 20 quarters since.
  • 1,429 funds tracked by Wall St. Rank held Cardinal Health as of Q1 2026.

Based on Bahl & Gaynor's 13F filing for Q1 2026, filed 7 May 2026.